Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.9K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.9K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

673
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
673
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

240
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
240
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

490
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
490
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

332
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
332
Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

358
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
358

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative Systems Pharmacology Modeling Amid the Rise of Agentic AI.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Follow-Up Bias in Tumor Dynamic Modeling: A Comparison of Classical and Neural-ODE Approaches.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Guideline-based strategies to identify severe cytokine release syndrome in COVID-19 and cancer immunotherapy using large-scale electronic health records.

Frontiers in digital health·2026
Same author

Causal Directed Acyclic Graphs to Mitigate Confounding Bias in Exposure-Response Analyses.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Enhancing Severe Neutropenia Prediction: PKPD-Informed Labeling for Machine Learning Models Trained on Real-World Data.

Clinical pharmacology and therapeutics·2025
Same author

Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti-ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies.

Clinical and translational science·2025

Related Experiment Video

Updated: Jan 14, 2026

Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

2.3K

Building Hybrid Pharmacometric-Machine Learning Models in Oncology Drug Development: Current State and

Anna Fochesato1, Logan Brooks2, Omid Bazgir2

  • 1Translational PKPD and Clinical Pharmacology, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.

CPT: Pharmacometrics & Systems Pharmacology
|October 17, 2025
PubMed
Summary
This summary is machine-generated.

Standardized workflows are crucial for hybrid pharmacometric-machine learning models (hPMxML) in oncology drug development. A proposed checklist enhances transparency, rigor, and reproducibility for these advanced models.

Keywords:
clinical drug developmentmachine learningpharmacometrics

More Related Videos

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.6K
Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

7.4K

Related Experiment Videos

Last Updated: Jan 14, 2026

Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

2.3K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.6K
Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

7.4K

Area of Science:

  • Pharmacometrics and Machine Learning
  • Computational Drug Development
  • Oncology Therapeutics

Background:

  • Hybrid pharmacometric-machine learning models (hPMxML) are increasingly used in oncology drug development and precision medicine.
  • Standardized workflows are lacking, hindering transparency, rigor, and effective communication for broader adoption.

Purpose of the Study:

  • To review existing pharmacometric (PMx) and machine learning (ML) reporting standards.
  • To evaluate these standards against hPMxML applications in oncology to identify deficiencies.
  • To propose mitigation strategies and a standardized checklist for hPMxML development and reporting.

Main Methods:

  • Review of PMx and ML reporting standards.
  • Evaluation of hPMxML oncology studies.
  • Identification of gaps in current practices.
  • Proposal of a comprehensive checklist for hPMxML development and reporting.

Main Results:

  • Identified deficiencies include insufficient benchmarking, lack of error propagation and feature stability assessments, limited external validation, and inappropriate performance metrics.
  • A checklist covering estimand definition, data curation, covariate selection, hyperparameter tuning, convergence, explainability, diagnostics, uncertainty quantification, and validation is proposed.

Conclusions:

  • The proposed checklist aims to enhance the reliability and reproducibility of hPMxML outputs.
  • Standardized reporting will foster trust and enable confident application of hPMxML in oncology clinical drug development.